Hua Xin

Dr. Hua Xin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HXHua Xin
Hua Xin
YSYue Sun
Yue Sun
JCJing Chen
Jing Chen
YWYing Wu
Ying Wu
JSJun Sha
Jun Sha
XZXiaoli Zhu
Xiaoli Zhu
Chemotherapy is an effective method to treat patients with advanced malignant tumors. However, tumor cells can develop resistance to multiple drugs during the therapy process, leading to treatment failure. Circular RNAs (circRNAs) are a new class of regulatory RNAs that can regulate endogenous gene expression. Previous studies revealed the diagnostic and prognostic value of circRNAs in malignant cancer and other diseases, but few reports have examined their association with clinical drug resistance. In this review, we summarize the up-to-date information regarding the role of circRNAs in the resistance of tumors to chemotherapy and discuss specific regulatory mechanisms. This analysis is expected to provide direction for the prevention and management of drug resistance in tumors.

1 July 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HXHua Xin
Hua Xin
HZHongming Zhang
Hongming Zhang
JJJinfang Jia
Jinfang Jia
SCShanshan Chen
Shanshan Chen
YSYue Sun
Yue Sun
XZXiaoli Zhu
Xiaoli Zhu
Chemotherapy and targeted therapy can significantly improve survival rates in cancer, but multiple drug resistance (MDR) limits the efficacy of these approaches. Understanding the molecular mechanisms underlying MDR is crucial for improving drug efficacy and clinical outcomes of patients with cancer. S100 proteins belong to a family of calcium-binding proteins and have various functions in tumor development. Increasing evidence demonstrates that the dysregulation of various S100 proteins contributes to the development of drug resistance in tumors, providing a basis for the development of predictive and prognostic biomarkers in cancer. Therefore, a combination of biological inhibitors or sensitizers of dysregulated S100 proteins could enhance therapeutic responses. In this review, we provide a detailed overview of the mechanisms by which S100 family members influence resistance of tumors to cancer treatment, with a focus on the development of effective strategies for overcoming MDR.

26 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
XWXiaodi Wu
Xiaodi Wu
HXHua Xin
Hua Xin
KXKe Xu
Ke Xu
YSYong Song
Yong Song
TLTangfeng Lv
Tangfeng Lv
Zebrafish is increasingly used as a model organism for cancer research because of its genetic and physiological similarities to humans. Modeling lung cancer (LC) in zebrafish has received significant attention. This review focuses on the insights gained from using zebrafish in LC research. These insights range from investigating the genetic and molecular mechanisms that contribute to the development and progression of LC to identifying potential drug targets, testing the efficacy and toxicity of new therapies, and applying zebrafish for personalized medicine studies. This review provides a comprehensive overview of the current state of LC research performed using zebrafish, highlights the advantages and limitations of this model organism, and discusses future directions in the field.